New England Biolabs, Inc. to Present Advances in Low-Input and Microbiome Next Generation Sequencing Sample Preparation at American Society of Human Genetics 2013

IPSWICH, Mass., Oct. 22, 2013 /PRNewswire/ -- New England Biolabs, Inc. (NEB^®) will host a workshop, which includes speakers from Genoptix (a Novartis company) and the MCW Cancer Center in Wisconsin, at the American Society of Human Genetics (ASHG) annual meeting. NEB will also present a number of scientific posters during the meeting.

(Logo: http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b )

The workshop's presentations, to occur Friday October 25^th from 12:30 to 2.00PM ET on the Boston Convention and Exhibition Center's second floor in room 209, are as follows:

• Development of Targeted Clinical Next Generation Sequencing (NGS) Assays
  for Limited FFPE Cancer Tissue Samples
  Wenge Shi, Ph.D., Genoptix Medical Laboratory, A Novartis Company
• Characterization of Plasma-derived Exosomal RNAs by Deep Sequencing
  Liang Wang, M.D.,Ph.D., MCW Cancer Center, Medical College of Wisconsin
• Sample Enrichment for Microbiome Studies
  Eileen Dimalanta, Ph.D., New England Biolabs, Inc.

NEB will present six posters at the meeting, including data on novel NEBNext^® Ultra technology for the facilitation of robust sequencing of scarce samples with low input amounts of exome DNA, genomic DNA and strand-specific RNA. Additional topics include enrichment of microbiome DNA from a variety of sample types.

"The next deluge of genomic data is the human metagenome, and human microbiome studies are one of the fastest growing segments of study. However, this is hampered by the extreme difficulty in obtaining useful genomic data from many samples, such as from saliva. While microbes constitute nine out of the ten cells in the human body, they have so little DNA that our own human DNA drowns theirs out. The arrival of the NEBNext microbiome enrichment methodology opens up the sequencing of many parts of the human microbiome that we weren't readily able to approach previously," said Fiona Stewart, Product Marketing Manager, Next Generation Sequencing at NEB.

For more information about the posters and workshops, visit www.neb.com/ashg2013. The locations and display dates for all of the posters are listed below:

Wednesday, October 23

• 1665W: A Fast Solution for NGS Library Prep with Low Nanogram DNA Input, for Multiple Sequencing Platforms
• 1674W: Streamlined Methods for miRNA and strand specific RNA Library Construction for the Ion Torrent PGM

Thursday, October 24

• 1675T: Novel Method for Multiplex Small-RNA Library Preparation with Improved Performance and Higher Sensitivity

Friday, October 25

• 1598F: Exome Sequencing Facilitated by A Fast Library Preparation Method with Low Nanogram DNA Input
• 1643F: Direct selection of Microbiome DNA from Host DNA
• 1595F:A Fast Solution to NGS Strand-specific RNA Library Prep

About New England Biolabs
Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, library preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and seven subsidiaries located in Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit www.neb.com

NEW ENGLAND BIOLABS^®, NEB^® AND NEBNEXT^® are registered trademarks of
New England Biolabs, Inc.
ULTRA is a trademark of New England Biolabs, Inc.

SOURCE New England Biolabs, Inc.